logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – Resected stage III BRAF-mutant melanoma: long-term benefit with adjuvant dabrafenib/trametinib

The 5-year analysis consolidates results of the COMBI-AD trial.